Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and hiv transmission: The "HIV treatment as prevention" experience in a Canadian setting

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Montaner, Julio S G ^a,b   Lima, Viviane D ^a,b   Harrigan, P Richard ^a,b   Lourenço, Lillian ^a   Yip, Benita ^a   Nosyk, Bohdan ^a,c   Wood, Evan ^a,b   Kerr, Thomas ^a,b   Shannon, Kate ^a,b   Moore, David ^a,b   Hogg, Robert S ^a,c   Barrios, Rolando ^a,e   Gilbert, Mark ^d   Krajden, Mel ^d   Gustafson, Reka ^e   Daly, Patricia ^e   Kendall, Perry ^f  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^e VANCOUVER COASTAL HEALTH   (Canada)

^f MINISTRY OF HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ARTICLE; CANADA; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG EFFECT; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; VIRUS LOAD; VIRUS TRANSMISSION; ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CYTOLOGY; DISEASE COURSE; HIV INFECTIONS; INCIDENCE; INFECTION CONTROL; LONGITUDINAL STUDY; POISSON DISTRIBUTION; PREVALENCE; PROCEDURES; REGISTER; REGRESSION ANALYSIS; TREATMENT OUTCOME; UTILIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; CD4-POSITIVE T-LYMPHOCYTES; COMMUNICABLE DISEASE CONTROL; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; POISSON DISTRIBUTION; PREVALENCE; REGISTRIES; REGRESSION ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84895757555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087872     Document Type: Article

References (61)

1. Lagakos S, Gable A (2008) Challenges to HIV prevention-seeking effective measures in the absence of a vaccine. N Engl J Med 358: 1543-1545. (Pubitemid 351519815)
2. Vermund SH, Allen KL, Karim QA (2009) HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS 4: 266-273.
3. Rotheram-Borus MJ, Swendeman D, Chovnick G (2009) The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 5: 143-167.
4. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D et al (2009) The challenge of finding a cure for HIV infection. Science 323(5919): 1304-7.
5. Coates TJ, Richter L, Caceres C (2008) Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 372(9639): 669-84.
6. Celum C, Baeten JM (2012) Antiretroviral-based HIV-1 prevention: antiretro-viral treatment and pre-exposure prophylaxis. Antivir Ther 17(8): 1483-93.
7. Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ et al (2013) Translation of Biomedical Prevention Strategies for HIV: Prospects and Pitfalls. J Acquir Immune Defic Syndr (Suppl 1): S12-25.
8. Montaner JS (2011) Treatment as prevention-a double hat-trick. Lancet 378(9787): 208-9.
9. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M et al (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368(9534): 531-6. (Pubitemid 44142776)
10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC et al HPTN 052 Study Team (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
11. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C et al (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402.
12. Jin F, Jansson J, Law M, Prestage GP, Zablotska I et al (2010) Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 24: 907-913.
13. Baggaley RF, White RG, Boily MC (2010) Infectiousness of HIV-infected homosexual men in the era of highly active antiretroviral therapy. AIDS 24: 2418-2420.
14. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C et al (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929. (Pubitemid 30177052)
15. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H et al (2007) The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 44: 1115-1122. (Pubitemid 46580284)
16. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K et al (1999) Percontact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 150: 306-311. (Pubitemid 29344958)
17. Zuckerman RA, Whittington WL, Celum CL, Collis TK, Lucchetti AJ et al (2004) Higher concentration of HIV RNA in rectal mucosa secretions than in blood and seminal plasma, among men who have sex with men, independent of antiretroviral therapy. J Infect Dis 190: 156-161. (Pubitemid 38858416)
18. Lafeuillade A, Cheret A, Hittinger G, Bernardini D, Cuquemelle C et al (2009) Rectal cell-associated HIV-1 RNA: a new marker ready for the clinic. HIV Clin Trials 10: 324-7.
19. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Michau C et al (2008) HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 22: 1880-1882.
20. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W et al (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375(9731): 2092-8.
21. Wood E, Kerr T, Marshall B, Li K, Zhang R et al (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 338: b1649.
22. Fang C, Hsu H, Twu S, Chen M, Chang Y et al (2004) Decreased HIV Transmission after a Policy of Providing Free Access to Highly Active Antiretroviral Therapy in Taiwan J Infect Dis 190(1): 879-85. (Pubitemid 39120963)
23. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E et al (2010) Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 5(6): e11068.
24. Kato M, Granich R, Bui DD, Tran HV, Nadol P et al (2013) : Towards elimination of HIV transmission. J Acquir Immune Defic Syndr [epub ahead of print]. PMID23714739.
25. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et al (1996) Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. J Amer Med Assoc 276(2): 146-54. Review.
26. Archibald C (2013) Personal communication, Public Health Agency of Canada.
27. Yang Q, Boulos D, Yan P, Zhang F, Remis RS et al (2010) Estimates of the number of prevalent and incident human immunodeficiency virus (HIV) infections in Canada, 2008. Can J Public Health 101(6): 486-90. PubMed PMID: 21370786.
28. Yan P, Zhang F, Wand H (2011) Using HIV Diagnostic Data to Estimate HIV Incidence: Method and Simulation. Statistical Communications in Infectious Diseases. Vol 3, Issue 1, Article 6. De Gruyter website. Available: http://www.bepress.com/scid/vol3/iss1/art6. Accessed July 9, 2013. doi: 10.2202/1948-4690.1011.
29. Wand H, Wilson D, Yan P, Gonnermann A, McDonald A et al (2009) Characterizing trends in HIV infection among men who have sex with men in Australia by birth cohorts: results from a modified back-projection method. J Int AIDS Soc. Sep 18;12: 19.
30. HIV/AIDS Annual Reports. BC Centre for Disease Control website. Available: http://www.bccdc.ca/util/about/annreport/default.htm. Accessed July 9, 2013.
31. British Columbia Centre for Excellence in HIV/AIDS Therapeutic Guidelines. BC Centre for Excellence in HIV/AIDS website. Available: http://www.cfenet.ubc.ca/therapeutic-guidelines. Accessed July 9, 2013.
32. Lima VD, Harrigan R, Murray M, Moore DM, Wood E et al (2008) Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS 22(17): 2371-80.
33. Montaner JS, Lima VD, Barrios R, Yip B, Wood E et al (2010) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376(9740): 532-9.
34. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D et al (2013) Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 21(1): 6-14.
35. British Columbia Vital Statistics Agency. Annual Reports. BC Vital Statistics Agency website. Available: http://www.vs.gov.bc.ca/stats/annual/. Accessed July 6, 2013.
36. International Statistical Classification of Diseases and Related Health Problems 10th Revision. World Health Organization website. Available: http://apps.who.int/classifications/icd10/browse/2010/en. Accessed July 6, 2013.
37. Sub-Provincial Population Projections - P.E.O.P.L.E. 2012 (Sep 2012). BC Stats website. Available: http://www.bcstats.gov.bc.ca/StatisticsBySubject/ Demography/PopulationProjections.aspx. Accessed July 6, 2013.
38. Hastie TJ, Tibshirani RJ (1990), Generalized Additive Models, New York: Chapman and Hall.
39. Wood SN (2006) Generalized Additive Models: An Introduction with R. Chapman & Hall/CRC Texts in Statistical Science, US.
40. McCullagh Peter, Nelder John (1989) Generalized Linear Models, Second Edition. Boca Raton: Chapman and Hall/CRC.
41. Muessig KE, Smith MK, Powers KA, Lo YR, Burns DN et al (2012) Does ART prevent HIV transmission among MSM? AIDS 26(18): 2267-73.
42. Stolte IG, Dukers NHTM, de Wit JBF, Fenema JS, Coutinho RA (2001) Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect 77: 184-186. (Pubitemid 32595739)
43. Wagner BG, Blower S (2012) Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One 7(9): e41212.
44. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G et al (2013) The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 27(3): 447-58.
45. Garnett GP, Becker S, Bertozzi S (2012) Treatment as prevention: translating efficacy trial results to population effectiveness. Curr Opin HIV AIDS 7(2): 157-63.
46. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML (2013) High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science eb2;339(6122): 966-71.
47. Hogg RS, Heath K, Lima VD, Nosyk B, Kanters S et al (2012) Disparities in the Burden of HIV/AIDS in Canada. PLOS ONE 7(11): E47260. PMID 23209549.
48. Kirk G, Galai N, Astemborski J, Linas B, Celentano D et al (2011) Decline in community viral load strongly associated with declining HIV incidence among IDU. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 27-March 2. Abstract 484.
49. Hull MW, Wu Z, Montaner JS (2012) Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS 6: 579-86. doi: 10.1097/COH.0b013e3283590617.
50. Wu Z (2013) Strategies to enhance TasP implementation, the China experience. Presented at the 2013 International Treatment as Prevention Workshop. Vancouver, BC, Canada. April 22-25.
51. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373(9657): 48-57.
52. Hontelez JAC, Lurie MN, Bärnighausen T, Bakker R, Baltussen R et al (2013) Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. PLoS Med 10(10): e1001534. doi:10.1371/journal.pmed.1001534.
53. Ford N, Hirnschall G (2013) Modelling the Strategic Use of Antiretroviral Therapy for the Treatment and Prevention of HIV. PLoS Med 10(10): e1001535. doi:10.1371/journal.pmed.1001535.
54. Doherty M (2013) 2013 WHO Consolidated Guidelines. Presented at the 2013 International Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 22-25.
55. Launch of the 2013 WHO consolidated ARV guidelines-What's the evidence? (2013) Presented at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia. June 30.
56. Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW et al (2010) Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 24: 1929-35.
57. Granich R, Kahn JG, Bennett B, Holmes CB, Garg N et al (2012) Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One 7(2): e30216. doi:10.1371/journal.-pone. 0030216;Epub 2012 Feb 13. PMID 22348000.
58. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F et al (2013) Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 369(18): 1715-25. doi:10.1056?NEJMsa1214720 PMID 2417517.
59. Lester RT, Morshed M, Gilbert M, Hottes T (2013) Syphilis and neurosyphilis increase to historic levels in BC. BCMJ 55(4): 204.
60. Werb D, Mills EJ, Montaner JS, Wood E (2010) Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users-a metaanalysis. Lancet Infect Dis 10(7): 464-9.
61. Kerr T (2012) Joint United Nations Programme on HIV/AIDS. Global Update: UNAIDS Report on the Global AIDS Epidemic. UNAIDS. ISBN 978-92-9173-592-1.